Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 3, 2007, Pages 145-150

  Mitsiakos, George ^a   Papaioannou, Georgia ^b   Giougi, Evagelia ^a   Karagianni, Paraskevi ^a   Garipidou, Vassilia ^a   Nikolaidis, Nikolaos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hematology Department   (Greece)

Author keywords

Hemorrhage; Neonates; Prematurity; Recombinant FVIIa

Indexed keywords

FIBRINOGEN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; VITAMIN K GROUP;

ALLERGIC REACTION; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; HEMOSTASIS; HUMAN; INFANT; MALE; MEDICAL RECORD; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPLASTIN TIME; TRANSFUSION;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FACTOR VII; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INFANT, NEWBORN; MALE; MAXIMUM TOLERATED DOSE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34247578732     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180335bcb     Document Type: Article

References (19)

1. Scientific Discussion (NovoSevens®) EMEA 2005. Available at: http://www.emea.eu.int/humandocs/PDFs/EPAR/Novoseven/072995en6.pdf
2. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol. 2006;43(suppl 1):105-107.
3. Thim L, Bjoern S, Christensen M, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry. 1988;27:7785-7793.
4. NovoSevens®, Novo Nordisk, Summary of Product Characteristics (SmPC) approved by Hellenic National Organization for Medicines (last update 1/2004).
5. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.
6. Laffan M, O'Connell N, Perry D, et al. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S35-S38.
7. Dunkley S, Mackie F. Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery: vascular graft remained patent. Hematology. 2003; 8:263-264.
8. Tobias J, Berkenbosch J, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4:49-51.
9. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002;32(suppl 1):41-44.
10. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003;37:268-272.
11. Mayer SA, Brun NC, Begtrup K, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
12. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis. 2003;14:117-120.
13. Mathew P, Winter S, Frost JD, et al. Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases. J Pediatr Hematol Oncol. 2003;25:499-502.
14. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med. 2006;7:34-39.
15. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol. 2002;22:672-674.
16. Millar CG, Stringer MD, Sugarman I, et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia. 2005;11:171-174.
17. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost. 2004;92:738-746.
18. Williams MD, Chalmers EA, Gibson BE. The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol. 2002;119:295-309.
19. Shirahata A, Shirakawa Y, Murakami C. Diagnosis of DIC in very low birth weight infants. Semin Thromb Hemost. 1998;24:467-471.